Kallikrein Inhibitor

Kallikrein Inhibitors (42):

Cat. No.	Product Name	Effect	Purity

HY-16735

Avoralstat	Inhibitor	98.0%
Avoralstat (BCX4161), a potent and orally active plasma kallikrein (PKK) inhibitor, is used for hereditary angioedema research.

HY-P4245

D-Pro-Phe-Arg-Chloromethylketone	Inhibitor	99.51%
D-Pro-Phe-Arg-Chloromethylketone, a inhibitor of coagulation factor XII and plasma kallikrein, plays an important role in thrombosis and inflammation.

HY-P99110

Lanadelumab	Inhibitor	99.74%
Lanadelumab (SHP643) is a human IgG1 monoclonal antibody against plasma kallikrein (pKal) with an K_i value of 0.12 nM. Lanadelumab inhibits both free and HMWK (high molecular weight kininogen)-bound pKal. Lanadelumab has the potential for the research of hereditary angioedema.

HY-132830

Sebetralstat	Inhibitor	99.58%
Sebetralstat (KVD900) is a plasma kallikrein inhibitor (WO2016083820). Sebetralstat can be used for the research of metabolic diseases.

HY-W662576

KVD-001	Inhibitor	99.73%
KVD-001 is a potent plasma kallikrein inhibitor. KVD-001 can be used for diabetic macular edema research.

HY-183667

JNJ-pan-AR	Inhibitor
JNJ-pan-AR is an orally active androgen receptor (AR) inhibitor with an IC₅₀ of 19 nM and a K_i of 8.4 nM against human wild-type AR. JNJ-pan-AR abolishes androgen-induced KLK2 and KLK3 mRNA expression and reduces androgen-dependent colony formation in prostate cancer cells. JNJ-pan-AR blocks AR nuclear translocation, inhibits PSA protein expression, and represses the growth of AR-dependent tumor cells and ARF877L-driven tumor xenografts. JNJ-pan-AR blocks transactivation and signaling of wild-type AR and various mutant AR variants. JNJ-pan-AR is applicable for research on castration-resistant prostate cancer.

HY-109127

Berotralstat	Inhibitor	99.70%
Berotralstat (BCX7353) is an orally active plasma kallikrein inhibitor. Berotralstat can reduce brain edema and is being studied for glioblastoma and hereditary angioedema.

HY-108814A

Ecallantide TFA	Inhibitor	99.54%
Ecallantide (DX-88) TFA is a specific recombinant plasma kallikrein inhibitor. Ecallantide inhibits the production of bradykinin. Ecallantide may be used to prevent acute attacks of angioedema.

HY-123133

PKSI-527	Inhibitor	98.04%
PKSI-527 is a new, highly selective plasma kallikrein inhibitor. PKSI-527 can suppress collagen-induced arthritis (CIA) by modifying the kallikrein-kinin system.

HY-122543

PPACK II diTFA	Inhibitor
PPACK II diTFA is an irreversible and specific glandular and plasma kallikreins inhibitor.

HY-145568

Feniralstat	Inhibitor	99.12%
Feniralstat (compound 30), a pyrazole derivative, is a potent kallikrein inhibitor with an IC₅₀ of 6.7 nM for Human plasma kallikrein (pKal). Feniralstat has no inhibition on Human KLKl, Human FXIa, Human Factor Xlla (all IC₅₀>40 μM).

HY-109127A

Berotralstat dihydrochloride	Inhibitor	98.67%
Berotralstat dihydrochloride (BCX7353 dihydrochloride) is an orally active plasma kallikrein inhibitor. Berotralstat can reduce brain edema and is being studied for glioblastoma and hereditary angioedema.

HY-153115

Plasma kallikrein-IN-4	Inhibitor	98.61%
Plasma kallikrein-IN-4 (Example 153) is a plasma kallikrein inhibitor with an IC₅₀ of 0.016 μM against human plasma kallikrein.

HY-126378

LSP-249	Inhibitor	99.05%
LSP-249 (example 35), extracted from patent WO2016011209A1, is a plasma kallikrein inhibitor under the study for angioedema, with an EC₅₀ less than 100 nM in cell.

HY-P4669

LM-030	Inhibitor
LM-030 (BPR277), cyclic depsipeptide, is a potent kallikrein-related peptidase 7 (KLK7) and human neutrophil elastase inhibitor with IC₅₀ values of 1 and 10 nM. LM-030 can be used for the study of Netherton syndrome.

HY-P991676

Eflumenibep alfa	Inhibitor
Eflumenibep alfa is a Kallikrein 5 inhibitor with anti-inflammatory activity. Eflumenibep alfa is a fusion protein that combines human SPINK2 with the human IgG1 Fc fragment at the C-terminus.

HY-148949A

Kallikrein 5-IN-2 TFA	Inhibitor	99.53%
Kallikrein 5-IN-2 TFA is the TFA salt form of Kallikrein 5-IN-2 (HY-148949). Kallikrein 5-IN-2 TFA is a selective inhibitor for kallikrein 5 (KLK5) with pIC₅₀ of 7.1. Kallikrein 5-IN-2 TFA is non-phototoxic (100 μg/mL) and non-irritant. Kallikrein 5-IN-2 is stable at pH 4-pH 8 under non-oxidative condition. Kallikrein 5-IN-2 is potent in ameliorating the Netherton syndrome.

HY-139787A

Donidalorsen sodium	Inhibitor
Donidalorsen (ISIS-721744; IONIS-PKK-LRX) sodium is an antisense oligonucleotide targeting prekallikrein (PKK). Donidalorsen sodium inhibits kallikrein activity and reduces the production of Bradykinin (HY-P0206) by specifically binding to and degrading PKK mRNA in the liver. Donidalorsen sodium can be used in the research of hereditary angioedema.

HY-P990459

Anti-KLK5/Kallikrein 5 Antibody	Inhibitor	98.49%
Anti-KLK5/Kallikrein 5 Antibody is a CHO-expressed human antibody that targets KLK5/Kallikrein 5. The Anti-KLK5/Kallikrein 5 Antibody has a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for the Anti-KLK5/Kallikrein 5 Antibody can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).

HY-139888

Plasma kallikrein-IN-1	Inhibitor
Plasma kallikrein-IN-1 is a PKK inhibitor with an IC₅₀ value of 0.5 nM.

Name
Email *

	Sorry, but the email address you supplied was invalid.